Endo Completes Sale of International Pharmaceuticals to Knight Therapeutics
Deal News | Jun 17, 2025 | PR Newswire Cision Endo, Inc.
Endo, Inc., a diversified pharmaceutical company, has confirmed the completion of its divestiture of the International Pharmaceuticals business to Knight Therapeutics Inc. This transaction was previously announced, and it includes operations primarily through Canada-based Paladin Pharma Inc. The deal is valued at up to $105 million, with $79 million settled at closing, $11 million held back, and potential future payments if certain milestones are achieved. This move is expected to streamline Endo's operations as it continues to focus on its core capabilities in developing life-enhancing therapies. Despite this strategic divestment, Endo has expressed caution regarding forward-looking statements, acknowledging the risks and uncertainties that accompany such moves, and how factors such as competitive conditions and regulatory changes could influence future performance.
Sectors
- Pharmaceuticals
- Mergers & Acquisitions
Geography
- United States – Endo, Inc. is based in Malvern, Pennsylvania, USA.
- Canada – The International Pharmaceuticals business was primarily operated through Canada-based Paladin Pharma Inc.
Industry
- Pharmaceuticals – The transaction involves pharmaceutical companies, Endo, Inc., and Knight Therapeutics Inc.
- Mergers & Acquisitions – The article details the divestiture of Endo's International Pharmaceuticals business unit.
Financials
- $105 million – Total possible cash consideration for the sale, including $79 million at closing, $11 million in holdbacks, and $15 million contingent on milestones.
- $79 million – Amount paid at the close of the transaction.
- $11 million – Holdbacks related to certain permitted conditions.
- $15 million – Future payments contingent upon milestone achievements.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Endo, Inc. | Vendor | Company | A diversified pharmaceutical company focused on developing life-enhancing therapies. |
| Knight Therapeutics Inc. | Buyer | Company | A Canadian specialty pharmaceutical company involved in acquiring the International Pharmaceuticals business from Endo. |
| Paladin Pharma Inc. | Operations | Company | Part of Endo’s International Pharmaceuticals business, based in Canada. |